Vitiligo medication safety registry for adults and teens
Part of Skin clinical trials.
This registry tracks the safety and effectiveness of vitiligo medications over time. It helps doctors learn how well treatments work for adults and teens with nonsegmental vitiligo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of vitiligo called nonsegmental vitiligo (white patches on both sides of your body), confirmed by a skin doctor.
- You are at least 12 years old.
- You are willing to give your personal information like name, date of birth, sex, and ZIP code.
- You are either starting a new prescribed vitiligo medication, already on one, or not currently using any vitiligo treatment.
- You are not taking part in a blinded clinical trial (a study where you don’t know what treatment you’re getting) for vitiligo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study creates a UK-wide registry (a secure list of patient information) for children and adults with vitiligo. Researchers will collect data over time to understand how vitiligo affects people, support research, and improve care.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.